Effects of Prenatal Aspirin on Postpartum Vascular Health
Protective Mechanisms of Prenatal Aspirin Therapy on Maternal Vascular Dysfunction Following Preeclampsia
This study tests if taking low-dose aspirin during pregnancy helps improve blood vessel health after giving birth in women who had preeclampsia compared to those with normal pregnancies.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 50 Years |
| Sex | Female |
| Sponsor | University of Iowa Academic / other |
| Locations | 1 site (Iowa City, Iowa) |
| Trial ID | NCT05653973 on ClinicalTrials.gov |
What this trial studies
This study investigates how low-dose aspirin therapy during pregnancy affects vascular function in women who have experienced preeclampsia. It focuses on understanding the mechanisms behind persistent vascular dysfunction postpartum by examining blood vessels in the skin. Participants will include women who had normal pregnancies and those who experienced preeclampsia, with varying use of low-dose aspirin. The study employs a minimally invasive technique to assess microvascular function.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 years or older, between 12 weeks to 5 years postpartum, with a history of either normal pregnancies or preeclampsia.
Not a fit: Patients currently using daily aspirin or those with certain health conditions, such as chronic kidney disease or skin diseases, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cardiovascular health outcomes for women who have had preeclampsia.
How similar studies have performed: While studies on low-dose aspirin in pregnancy are common, this specific investigation into postpartum vascular function is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion: * 18 years or older, * 12 weeks to 5 years postpartum * and one of the following: 1. women who had a normal pregnancy and did not use low does aspirin (LDA) during pregnancy, 2. women who had a normal pregnancy and used LDA during pregnancy, 3. women who had preeclampsia and did not use LDA during pregnancy, 4. women who had preeclampsia and used LDA during pregnancy. Exclusion: * current daily aspirin use, * skin diseases, * current tobacco use, * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * current pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs.
Where this trial is running
Iowa City, Iowa
- University of Iowa — Iowa City, Iowa, United States (Recruiting)
Study contacts
- Study coordinator: Anna Reid-Stanhewicz, PHD
- Email: anna-stanhewicz@uiowa.edu
- Phone: 319-467-1732
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.